Tags

Type your tag names separated by a space and hit enter

The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Therap Adv Gastroenterol 2015; 8(3):136-42TA

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder. Serotonin (5-HT) is known to play a physiological and pathophysiological role in the regulation of gastrointestinal function. In experimental studies, 5-HT3 receptor antagonists have been reported to slow colon transit, to blunt gastrocolonic reflex, and to reduce rectal sensitivity. Alosetron and cilansetron, potent and selective 5-HT3 receptor antagonists, have proven efficacy in the treatment of IBS with diarrhea (IBS-D). However, alosetron was voluntarily withdrawn due to postmarketing reports of ischemic colitis and complications of constipation, and cilansetron was never marketed. Currently alosetron is available under a risk management program for women with severe IBS-D. Ramosetron is another potent and selective 5-HT3 receptor antagonist, which has been marketed in Japan, South Korea, and Taiwan. In animal studies, ramosetron reduced defecation induced by corticotrophin-releasing hormone and had inhibitory effects on colonic nociception. In two randomized controlled studies including 957 patients with IBS-D, ramosetron increased monthly responder rates of patient-reported global assessment of IBS symptom relief compared with placebo. Ramosetron was also as effective as mebeverine in male patients with IBS-D. In a recent randomized controlled trial with 343 male patients with IBS-D, ramosetron has proved effective in improving stool consistency, relieving abdominal pain/discomfort, and improving health-related quality of life. Regarding safety, ramosetron is associated with a lower incidence of constipation compared with other 5-HT3 receptor antagonists and has not been associated with ischemic colitis. Although further large prospective studies are needed to assess whether ramosetron is effective for female patients with IBS-D and to evaluate its long-term safety, ramosetron appears to be one of the most promising agents for patients with IBS-D.

Authors+Show Affiliations

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25949526

Citation

Min, Yang Won, and Poong-Lyul Rhee. "The Clinical Potential of Ramosetron in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)." Therapeutic Advances in Gastroenterology, vol. 8, no. 3, 2015, pp. 136-42.
Min YW, Rhee PL. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol. 2015;8(3):136-42.
Min, Y. W., & Rhee, P. L. (2015). The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therapeutic Advances in Gastroenterology, 8(3), pp. 136-42. doi:10.1177/1756283X15572580.
Min YW, Rhee PL. The Clinical Potential of Ramosetron in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D). Therap Adv Gastroenterol. 2015;8(3):136-42. PubMed PMID: 25949526.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). AU - Min,Yang Won, AU - Rhee,Poong-Lyul, PY - 2015/5/8/entrez PY - 2015/5/8/pubmed PY - 2015/5/8/medline KW - 5-HT3 KW - diarrhea KW - irritable bowel syndrome KW - ramosetron KW - serotonin SP - 136 EP - 42 JF - Therapeutic advances in gastroenterology JO - Therap Adv Gastroenterol VL - 8 IS - 3 N2 - Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder. Serotonin (5-HT) is known to play a physiological and pathophysiological role in the regulation of gastrointestinal function. In experimental studies, 5-HT3 receptor antagonists have been reported to slow colon transit, to blunt gastrocolonic reflex, and to reduce rectal sensitivity. Alosetron and cilansetron, potent and selective 5-HT3 receptor antagonists, have proven efficacy in the treatment of IBS with diarrhea (IBS-D). However, alosetron was voluntarily withdrawn due to postmarketing reports of ischemic colitis and complications of constipation, and cilansetron was never marketed. Currently alosetron is available under a risk management program for women with severe IBS-D. Ramosetron is another potent and selective 5-HT3 receptor antagonist, which has been marketed in Japan, South Korea, and Taiwan. In animal studies, ramosetron reduced defecation induced by corticotrophin-releasing hormone and had inhibitory effects on colonic nociception. In two randomized controlled studies including 957 patients with IBS-D, ramosetron increased monthly responder rates of patient-reported global assessment of IBS symptom relief compared with placebo. Ramosetron was also as effective as mebeverine in male patients with IBS-D. In a recent randomized controlled trial with 343 male patients with IBS-D, ramosetron has proved effective in improving stool consistency, relieving abdominal pain/discomfort, and improving health-related quality of life. Regarding safety, ramosetron is associated with a lower incidence of constipation compared with other 5-HT3 receptor antagonists and has not been associated with ischemic colitis. Although further large prospective studies are needed to assess whether ramosetron is effective for female patients with IBS-D and to evaluate its long-term safety, ramosetron appears to be one of the most promising agents for patients with IBS-D. SN - 1756-283X UR - https://www.unboundmedicine.com/medline/citation/25949526/The_clinical_potential_of_ramosetron_in_the_treatment_of_irritable_bowel_syndrome_with_diarrhea__IBS_D__ L2 - http://journals.sagepub.com/doi/full/10.1177/1756283X15572580?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -